February 2006 FDA Pipeline

February 1, 2006

New molecular entities

New molecular entities

Nexavar
Sorafenib tablets
Bayer/OnyxORAL THERAPY APPROVED FOR THE TREATMENT OF ADVANCED RENAL CELL CARCINOMA

New indications

Avelox
Moxifloxacin
Bayer/Schering-PloughFLUOROQUINOLONE ANTIBIOTIC APPROVED FOR CIAI

Dosing. The recommended dose of moxifloxacin is 400 mg (orally or as an IV infusion) once every 24 hours. For cIAIs, therapy should usually be initiated with the IV formulation, and the duration of therapy should last from 5 to 14 days.